Second, we have escalated the dose level through 160 milligrams daily and are now evaluating 220 milligrams daily while also continuing to backfill the 120- and 160-milligram dose levels. We are encouraged that we continue to accumulate clinical evidence of antitumor activity for RMC-6236 at doses that appear to be well tolerated. Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Marc Frahm - TD Cowen Eric Joseph - JPMorgan Chase & Co. Michael Schmidt - Guggenh ...